Jim Palma is Chief Executive Officer of TargetCancer Foundation (TCF). Since joining TargetCancer Foundation in 2010, Jim has overseen its growth from a small Boston-based start-up to a nationally recognized foundation supporting comprehensive rare cancer research programs and patient support services.

Jim is a member of the Board of Directors of the National Organization for Rare Disorders (NORD) and is a founding Co-Chair of the NORD Rare Cancers Coalition. In addition, Jim serves on the Advisory Board of the Transformative Rare Cancer Initiative (TRACER) at the Fred Hutchinson Cancer Center, and is a Steering Committee member at the Global Cholangiocarcinoma Alliance. Jim also serves as a member of the Programmatic Panel of the US Army Medical Research and Development Command Rare Cancers Research Program.

Prior to joining TargetCancer Foundation, Jim spent eleven years at Fidelity Investments in Boston, MA. Jim completed studies at the Institute for Nonprofit Management and Leadership at the Questrom School of Business at Boston University, and received his B.A. from Loyola University Maryland

We are excited to expand our network internationally through our participation in WIN. We admire the great work that WIN has carried out through innovative trials like WINTHER and are excited to learn from WIN’s expertise and also identify avenues for collaboration. We are excited to be a member and to help build an advocacy presence at WIN.